Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 108 | 2024 | 5169 | 5.610 |
Why?
|
Boronic Acids | 33 | 2021 | 965 | 1.810 |
Why?
|
Antineoplastic Agents | 56 | 2023 | 13655 | 1.740 |
Why?
|
Pyrazines | 31 | 2015 | 1231 | 1.400 |
Why?
|
Thalidomide | 27 | 2015 | 888 | 1.210 |
Why?
|
Stromal Cells | 14 | 2019 | 1353 | 1.180 |
Why?
|
Drug Resistance, Neoplasm | 24 | 2023 | 5163 | 1.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 17 | 2021 | 8425 | 0.960 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2021 | 987 | 0.910 |
Why?
|
Xenograft Model Antitumor Assays | 15 | 2021 | 3557 | 0.810 |
Why?
|
Cell Line, Tumor | 39 | 2023 | 16665 | 0.780 |
Why?
|
Tumor Cells, Cultured | 19 | 2021 | 6313 | 0.760 |
Why?
|
Proteasome Endopeptidase Complex | 9 | 2021 | 1333 | 0.750 |
Why?
|
Cytotoxicity, Immunologic | 4 | 2023 | 1368 | 0.750 |
Why?
|
Apoptosis | 31 | 2023 | 9715 | 0.730 |
Why?
|
Drug Screening Assays, Antitumor | 9 | 2014 | 731 | 0.700 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 290 | 0.680 |
Why?
|
NF-kappa B | 11 | 2024 | 2500 | 0.670 |
Why?
|
Luminescent Measurements | 2 | 2012 | 405 | 0.660 |
Why?
|
Neoplastic Stem Cells | 5 | 2021 | 1376 | 0.640 |
Why?
|
Killer Cells, Natural | 5 | 2023 | 2133 | 0.620 |
Why?
|
Cell Survival | 17 | 2021 | 5872 | 0.530 |
Why?
|
Histone Deacetylase Inhibitors | 8 | 2013 | 789 | 0.530 |
Why?
|
Embryo, Mammalian | 1 | 2021 | 1692 | 0.500 |
Why?
|
Adaptation, Physiological | 1 | 2021 | 1310 | 0.470 |
Why?
|
Protease Inhibitors | 8 | 2009 | 790 | 0.460 |
Why?
|
Mice, SCID | 11 | 2017 | 2715 | 0.460 |
Why?
|
Mice, Inbred NOD | 7 | 2021 | 1875 | 0.450 |
Why?
|
Oligopeptides | 4 | 2018 | 1176 | 0.440 |
Why?
|
Signal Transduction | 23 | 2020 | 23387 | 0.440 |
Why?
|
Plant Growth Regulators | 1 | 2012 | 50 | 0.430 |
Why?
|
Oxylipins | 1 | 2012 | 49 | 0.430 |
Why?
|
Cyclopentanes | 1 | 2012 | 93 | 0.430 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2020 | 1509 | 0.420 |
Why?
|
Hematologic Neoplasms | 4 | 2023 | 1820 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2021 | 11472 | 0.410 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2021 | 1860 | 0.410 |
Why?
|
Insulin-Like Growth Factor I | 6 | 2009 | 2014 | 0.410 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2012 | 83 | 0.400 |
Why?
|
Thiocyanates | 1 | 2011 | 70 | 0.400 |
Why?
|
Isothiocyanates | 1 | 2011 | 51 | 0.400 |
Why?
|
Depsipeptides | 2 | 2010 | 94 | 0.400 |
Why?
|
Pteridines | 1 | 2011 | 45 | 0.400 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2021 | 2915 | 0.390 |
Why?
|
Acetates | 1 | 2012 | 312 | 0.390 |
Why?
|
Ubiquitin | 3 | 2017 | 849 | 0.390 |
Why?
|
Cyclin-Dependent Kinase 9 | 2 | 2021 | 66 | 0.380 |
Why?
|
Enzyme Inhibitors | 9 | 2014 | 3800 | 0.380 |
Why?
|
Mice | 38 | 2023 | 81045 | 0.370 |
Why?
|
Cyclin-Dependent Kinases | 3 | 2023 | 670 | 0.360 |
Why?
|
Immunomodulation | 2 | 2013 | 540 | 0.360 |
Why?
|
Ubiquitins | 1 | 2012 | 383 | 0.360 |
Why?
|
Coculture Techniques | 6 | 2013 | 1341 | 0.360 |
Why?
|
Tumor Microenvironment | 8 | 2023 | 3564 | 0.350 |
Why?
|
Paraproteinemias | 4 | 2005 | 247 | 0.350 |
Why?
|
Lactams, Macrocyclic | 6 | 2013 | 319 | 0.350 |
Why?
|
Stem Cell Transplantation | 5 | 2012 | 1618 | 0.350 |
Why?
|
Bone Marrow | 10 | 2018 | 2941 | 0.340 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 127 | 0.340 |
Why?
|
Cell Cycle | 10 | 2017 | 2964 | 0.330 |
Why?
|
HSP90 Heat-Shock Proteins | 7 | 2013 | 434 | 0.330 |
Why?
|
Humans | 143 | 2024 | 742088 | 0.330 |
Why?
|
Gene Expression Profiling | 12 | 2019 | 9410 | 0.330 |
Why?
|
Imidazoles | 5 | 2013 | 1205 | 0.330 |
Why?
|
Benzoquinones | 5 | 2013 | 201 | 0.320 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 623 | 0.320 |
Why?
|
Animals | 46 | 2023 | 168561 | 0.320 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2522 | 0.310 |
Why?
|
Protein Kinase Inhibitors | 7 | 2018 | 5522 | 0.310 |
Why?
|
Dexamethasone | 11 | 2021 | 1949 | 0.310 |
Why?
|
Proto-Oncogene Proteins | 4 | 2012 | 4553 | 0.300 |
Why?
|
Drug Discovery | 3 | 2014 | 1057 | 0.300 |
Why?
|
Receptor, IGF Type 1 | 2 | 2014 | 390 | 0.300 |
Why?
|
Neoplasms | 9 | 2023 | 21596 | 0.290 |
Why?
|
High-Throughput Screening Assays | 2 | 2012 | 944 | 0.290 |
Why?
|
Epigenesis, Genetic | 4 | 2021 | 3639 | 0.280 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2021 | 3497 | 0.270 |
Why?
|
Plasma Cells | 3 | 2020 | 592 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2018 | 10943 | 0.260 |
Why?
|
Genes, ras | 3 | 2018 | 691 | 0.250 |
Why?
|
Drug Synergism | 10 | 2018 | 1791 | 0.250 |
Why?
|
Pyrimidines | 7 | 2018 | 2933 | 0.250 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2005 | 199 | 0.250 |
Why?
|
Cell Cycle Proteins | 3 | 2014 | 3444 | 0.240 |
Why?
|
Quinolines | 1 | 2009 | 719 | 0.240 |
Why?
|
Up-Regulation | 6 | 2021 | 4211 | 0.240 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 2003 | 1052 | 0.240 |
Why?
|
Genomics | 5 | 2024 | 5692 | 0.240 |
Why?
|
Cell Proliferation | 13 | 2021 | 10472 | 0.240 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2004 | 77 | 0.230 |
Why?
|
Membrane Glycoproteins | 6 | 2018 | 3769 | 0.230 |
Why?
|
Adjuvants, Immunologic | 3 | 2003 | 1000 | 0.230 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2013 | 491 | 0.220 |
Why?
|
Remission Induction | 7 | 2021 | 2384 | 0.220 |
Why?
|
B-Lymphocytes | 6 | 2021 | 4664 | 0.220 |
Why?
|
Salvage Therapy | 6 | 2010 | 1269 | 0.210 |
Why?
|
Drug Evaluation, Preclinical | 5 | 2013 | 1372 | 0.210 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 1596 | 0.210 |
Why?
|
Receptors, Purinergic P2 | 1 | 2003 | 152 | 0.210 |
Why?
|
Gangliosides | 1 | 2022 | 140 | 0.200 |
Why?
|
Mice, Nude | 3 | 2021 | 3689 | 0.200 |
Why?
|
Cell Line | 6 | 2021 | 15994 | 0.200 |
Why?
|
Prostatic Neoplasms | 2 | 2020 | 11039 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9185 | 0.200 |
Why?
|
Genes, Overlapping | 1 | 2021 | 36 | 0.200 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2021 | 329 | 0.200 |
Why?
|
Interleukin-6 | 7 | 2010 | 3199 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2013 | 2502 | 0.190 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2021 | 107 | 0.190 |
Why?
|
Proteomics | 5 | 2021 | 3618 | 0.180 |
Why?
|
Chromosome Deletion | 1 | 2005 | 1400 | 0.180 |
Why?
|
Furans | 1 | 2021 | 194 | 0.180 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 407 | 0.180 |
Why?
|
Immunity, Innate | 1 | 2012 | 2956 | 0.180 |
Why?
|
Bone Marrow Cells | 5 | 2013 | 2513 | 0.180 |
Why?
|
Piperazines | 2 | 2009 | 2488 | 0.180 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2021 | 199 | 0.170 |
Why?
|
Tumor Burden | 3 | 2011 | 1905 | 0.170 |
Why?
|
Antigens, Surface | 1 | 2004 | 1663 | 0.170 |
Why?
|
Apoptosis Regulatory Proteins | 7 | 2023 | 1158 | 0.170 |
Why?
|
IMP Dehydrogenase | 1 | 2018 | 34 | 0.170 |
Why?
|
Recurrence | 14 | 2014 | 8333 | 0.160 |
Why?
|
Immunologic Factors | 4 | 2013 | 1575 | 0.160 |
Why?
|
Biphenyl Compounds | 2 | 2021 | 914 | 0.160 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2023 | 1366 | 0.160 |
Why?
|
Drug Therapy, Combination | 4 | 2021 | 6483 | 0.160 |
Why?
|
Boron Compounds | 2 | 2021 | 178 | 0.160 |
Why?
|
Exosomes | 1 | 2023 | 412 | 0.160 |
Why?
|
Mucin-1 | 1 | 2023 | 543 | 0.160 |
Why?
|
Flow Cytometry | 4 | 2012 | 5975 | 0.160 |
Why?
|
Clinical Trials as Topic | 13 | 2016 | 7901 | 0.160 |
Why?
|
Pyrroles | 3 | 2018 | 1143 | 0.160 |
Why?
|
Tumor Necrosis Factor-alpha | 6 | 2006 | 4414 | 0.160 |
Why?
|
Nuclear Respiratory Factor 1 | 1 | 2017 | 23 | 0.160 |
Why?
|
Janus Kinases | 3 | 2018 | 244 | 0.150 |
Why?
|
Oncogene Proteins | 2 | 2021 | 749 | 0.150 |
Why?
|
Treatment Outcome | 21 | 2021 | 62966 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2023 | 1434 | 0.150 |
Why?
|
Arsenicals | 1 | 2017 | 124 | 0.150 |
Why?
|
Piperidines | 2 | 2018 | 1602 | 0.150 |
Why?
|
Glycoproteins | 1 | 2005 | 2260 | 0.150 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2021 | 628 | 0.140 |
Why?
|
Sulfides | 1 | 2017 | 166 | 0.140 |
Why?
|
Nuclear Proteins | 4 | 2017 | 5851 | 0.140 |
Why?
|
Histone Deacetylases | 2 | 2013 | 729 | 0.140 |
Why?
|
Glycine | 2 | 2021 | 671 | 0.140 |
Why?
|
Maximum Tolerated Dose | 4 | 2021 | 891 | 0.140 |
Why?
|
Drug Repositioning | 1 | 2018 | 229 | 0.140 |
Why?
|
Oxides | 1 | 2017 | 405 | 0.130 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2019 | 450 | 0.130 |
Why?
|
Transcription, Genetic | 5 | 2021 | 7721 | 0.130 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20774 | 0.130 |
Why?
|
Disease Models, Animal | 6 | 2021 | 18006 | 0.130 |
Why?
|
Cyclophilin A | 1 | 2015 | 56 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2010 | 700 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 2 | 2012 | 1835 | 0.130 |
Why?
|
Ovary | 1 | 2019 | 981 | 0.130 |
Why?
|
Angiogenesis Inhibitors | 3 | 2011 | 2038 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2014 | 2455 | 0.120 |
Why?
|
Genome | 1 | 2023 | 1803 | 0.120 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2014 | 59 | 0.120 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 4 | 2005 | 197 | 0.120 |
Why?
|
GATA2 Transcription Factor | 1 | 2014 | 161 | 0.120 |
Why?
|
Neuroblastoma | 1 | 2022 | 1225 | 0.120 |
Why?
|
Phenothiazines | 1 | 2014 | 63 | 0.120 |
Why?
|
Transcription Factors | 7 | 2021 | 12164 | 0.120 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9274 | 0.120 |
Why?
|
Prostate-Specific Antigen | 1 | 2004 | 2458 | 0.120 |
Why?
|
Phenylenediamines | 1 | 2014 | 90 | 0.120 |
Why?
|
Proteome | 3 | 2018 | 1790 | 0.120 |
Why?
|
Syndecan-1 | 2 | 2012 | 164 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1377 | 0.120 |
Why?
|
Phosphorylation | 6 | 2014 | 8436 | 0.120 |
Why?
|
HEK293 Cells | 2 | 2021 | 4200 | 0.110 |
Why?
|
Teratogens | 1 | 2013 | 112 | 0.110 |
Why?
|
Immunotherapy | 4 | 2022 | 4414 | 0.110 |
Why?
|
Adenosine Triphosphatases | 1 | 2017 | 836 | 0.110 |
Why?
|
Azepines | 2 | 2014 | 336 | 0.110 |
Why?
|
Interleukin-1 Receptor Accessory Protein | 1 | 2012 | 5 | 0.110 |
Why?
|
Poly(ADP-ribose) Polymerases | 3 | 2011 | 441 | 0.110 |
Why?
|
Cell Communication | 4 | 2018 | 1619 | 0.110 |
Why?
|
Survival Analysis | 7 | 2019 | 10248 | 0.110 |
Why?
|
Adrenergic beta-2 Receptor Antagonists | 1 | 2012 | 9 | 0.110 |
Why?
|
Disease-Free Survival | 5 | 2012 | 6891 | 0.110 |
Why?
|
Penicillium | 1 | 2012 | 22 | 0.110 |
Why?
|
Ikaros Transcription Factor | 1 | 2013 | 214 | 0.110 |
Why?
|
Xanthones | 1 | 2012 | 25 | 0.110 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2012 | 48 | 0.110 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2186 | 0.100 |
Why?
|
Protein Phosphatase 2 | 1 | 2014 | 229 | 0.100 |
Why?
|
Clodronic Acid | 1 | 2011 | 60 | 0.100 |
Why?
|
Sulfoxides | 1 | 2011 | 48 | 0.100 |
Why?
|
Gene Knockdown Techniques | 4 | 2021 | 1655 | 0.100 |
Why?
|
Caspases | 5 | 2012 | 928 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1932 | 0.100 |
Why?
|
Female | 35 | 2021 | 379592 | 0.100 |
Why?
|
Leukemia | 2 | 2012 | 1507 | 0.100 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 261 | 0.100 |
Why?
|
Cell Compartmentation | 1 | 2012 | 402 | 0.100 |
Why?
|
Down-Regulation | 4 | 2013 | 3001 | 0.100 |
Why?
|
Chromatin | 2 | 2020 | 2917 | 0.100 |
Why?
|
G1 Phase | 1 | 2012 | 415 | 0.090 |
Why?
|
Bone Diseases | 1 | 2014 | 416 | 0.090 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 354 | 0.090 |
Why?
|
Cell Fractionation | 1 | 2011 | 252 | 0.090 |
Why?
|
Benzoates | 1 | 2012 | 217 | 0.090 |
Why?
|
Hydrazines | 1 | 2012 | 220 | 0.090 |
Why?
|
Transplantation, Heterologous | 3 | 2004 | 2382 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2005 | 595 | 0.090 |
Why?
|
Peptide Hydrolases | 1 | 2013 | 627 | 0.090 |
Why?
|
Inhibitory Concentration 50 | 1 | 2011 | 459 | 0.090 |
Why?
|
Blood Coagulation Factors | 1 | 2012 | 355 | 0.090 |
Why?
|
Asthenia | 1 | 2010 | 16 | 0.090 |
Why?
|
Quinazolinones | 1 | 2012 | 221 | 0.090 |
Why?
|
K562 Cells | 1 | 2012 | 632 | 0.090 |
Why?
|
Cell Division | 2 | 2011 | 4564 | 0.090 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 577 | 0.090 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2014 | 670 | 0.090 |
Why?
|
Osteolysis | 1 | 2011 | 270 | 0.090 |
Why?
|
Myelodysplastic Syndromes | 2 | 2012 | 1351 | 0.090 |
Why?
|
Peptides, Cyclic | 2 | 2010 | 401 | 0.090 |
Why?
|
Triazoles | 2 | 2014 | 907 | 0.090 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 2077 | 0.090 |
Why?
|
Tamoxifen | 1 | 2014 | 980 | 0.090 |
Why?
|
Male | 32 | 2021 | 349538 | 0.090 |
Why?
|
Drosophila Proteins | 1 | 2018 | 1699 | 0.090 |
Why?
|
Autophagy | 1 | 2017 | 1301 | 0.090 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2011 | 177 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1834 | 0.080 |
Why?
|
Receptors, Cytokine | 1 | 2009 | 261 | 0.080 |
Why?
|
Caspase 3 | 1 | 2011 | 759 | 0.080 |
Why?
|
Mitochondria | 2 | 2012 | 3520 | 0.080 |
Why?
|
Urochordata | 1 | 2008 | 21 | 0.080 |
Why?
|
Small Molecule Libraries | 1 | 2014 | 721 | 0.080 |
Why?
|
Biological Availability | 1 | 2009 | 396 | 0.080 |
Why?
|
Phosphorylcholine | 1 | 2009 | 162 | 0.080 |
Why?
|
Transplantation, Autologous | 2 | 2012 | 2123 | 0.080 |
Why?
|
Neoplasm Transplantation | 2 | 2003 | 2085 | 0.080 |
Why?
|
Prognosis | 9 | 2019 | 29010 | 0.080 |
Why?
|
Receptors, Androgen | 1 | 2014 | 1057 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2723 | 0.080 |
Why?
|
Immunoblotting | 2 | 2009 | 1683 | 0.080 |
Why?
|
Endothelial Cells | 2 | 2012 | 3455 | 0.080 |
Why?
|
Genome, Human | 1 | 2021 | 4420 | 0.080 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 222 | 0.080 |
Why?
|
Seawater | 1 | 2008 | 121 | 0.080 |
Why?
|
Plasmacytoma | 2 | 2015 | 182 | 0.080 |
Why?
|
Rats, Inbred F344 | 1 | 2009 | 862 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2020 | 2948 | 0.080 |
Why?
|
Substrate Specificity | 1 | 2012 | 1802 | 0.080 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 559 | 0.080 |
Why?
|
Mass Spectrometry | 4 | 2014 | 2203 | 0.080 |
Why?
|
Glucuronidase | 1 | 2009 | 207 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 781 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2014 | 930 | 0.070 |
Why?
|
Osteoclasts | 1 | 2011 | 729 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1052 | 0.070 |
Why?
|
Hydroxamic Acids | 2 | 2008 | 495 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 380 | 0.070 |
Why?
|
Ubiquitination | 1 | 2012 | 1011 | 0.070 |
Why?
|
Morpholines | 1 | 2010 | 561 | 0.070 |
Why?
|
Diphosphonates | 1 | 2011 | 625 | 0.070 |
Why?
|
Administration, Oral | 3 | 2011 | 3913 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1683 | 0.070 |
Why?
|
Purines | 1 | 2010 | 593 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2009 | 2938 | 0.070 |
Why?
|
Blotting, Western | 2 | 2011 | 5180 | 0.070 |
Why?
|
Fibrinogen | 1 | 2009 | 894 | 0.070 |
Why?
|
Monocytes | 2 | 2012 | 2593 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2107 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1820 | 0.070 |
Why?
|
Drug Interactions | 1 | 2011 | 1458 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 2024 | 0.070 |
Why?
|
Staurosporine | 3 | 2013 | 251 | 0.070 |
Why?
|
Renal Insufficiency | 1 | 2012 | 802 | 0.070 |
Why?
|
Cysteine Proteinase Inhibitors | 2 | 2003 | 190 | 0.070 |
Why?
|
Biomimetic Materials | 1 | 2007 | 179 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6096 | 0.070 |
Why?
|
Drug Combinations | 1 | 2011 | 1961 | 0.070 |
Why?
|
Oncogenes | 2 | 2018 | 1263 | 0.070 |
Why?
|
Pyrazoles | 2 | 2014 | 1970 | 0.070 |
Why?
|
Benzodiazepines | 1 | 2011 | 1101 | 0.070 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2009 | 484 | 0.070 |
Why?
|
CpG Islands | 1 | 2009 | 1170 | 0.060 |
Why?
|
Mutant Proteins | 1 | 2007 | 500 | 0.060 |
Why?
|
Chemokines, CXC | 1 | 2007 | 422 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2012 | 1402 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2011 | 1782 | 0.060 |
Why?
|
Leukemia, Plasma Cell | 1 | 2005 | 48 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4823 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2008 | 3920 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2011 | 774 | 0.060 |
Why?
|
DNA-Binding Proteins | 4 | 2020 | 9639 | 0.060 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3847 | 0.060 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2009 | 834 | 0.060 |
Why?
|
Time Factors | 4 | 2014 | 40054 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 3 | 2012 | 3381 | 0.060 |
Why?
|
Iron | 1 | 2012 | 1773 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3584 | 0.060 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10163 | 0.060 |
Why?
|
Biological Therapy | 1 | 2005 | 138 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4751 | 0.060 |
Why?
|
Cell Differentiation | 3 | 2016 | 11470 | 0.060 |
Why?
|
Histones | 1 | 2013 | 2597 | 0.060 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 279 | 0.060 |
Why?
|
Retinal Neoplasms | 1 | 2005 | 144 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2014 | 3020 | 0.050 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2003 | 85 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2023 | 91 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 2417 | 0.050 |
Why?
|
Hematopoiesis | 1 | 2012 | 2066 | 0.050 |
Why?
|
Receptors, Notch | 2 | 2020 | 739 | 0.050 |
Why?
|
Retinoblastoma | 1 | 2005 | 318 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4801 | 0.050 |
Why?
|
Survival Rate | 3 | 2012 | 12773 | 0.050 |
Why?
|
bcl-X Protein | 1 | 2023 | 411 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1638 | 0.050 |
Why?
|
Cytokines | 3 | 2013 | 7317 | 0.050 |
Why?
|
Blood Proteins | 1 | 2007 | 1122 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12220 | 0.050 |
Why?
|
HL-60 Cells | 2 | 2012 | 365 | 0.050 |
Why?
|
Animals, Genetically Modified | 2 | 2018 | 1546 | 0.050 |
Why?
|
Thiazoles | 2 | 2012 | 1484 | 0.050 |
Why?
|
Protein Array Analysis | 1 | 2003 | 411 | 0.050 |
Why?
|
Fluorescence | 1 | 2003 | 751 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2007 | 995 | 0.050 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 154 | 0.050 |
Why?
|
Membrane Potential, Mitochondrial | 2 | 2012 | 297 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2011 | 5095 | 0.050 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2021 | 300 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2003 | 853 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1801 | 0.050 |
Why?
|
Bone and Bones | 1 | 2011 | 2575 | 0.050 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2021 | 417 | 0.050 |
Why?
|
Cell Death | 2 | 2017 | 1695 | 0.040 |
Why?
|
Microdissection | 1 | 2019 | 152 | 0.040 |
Why?
|
Mutation | 3 | 2013 | 29717 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2015 | 11001 | 0.040 |
Why?
|
Cyclin D1 | 1 | 2021 | 462 | 0.040 |
Why?
|
Prodrugs | 1 | 2021 | 268 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2003 | 1097 | 0.040 |
Why?
|
Thioredoxins | 1 | 2020 | 213 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 2002 | 686 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2005 | 3502 | 0.040 |
Why?
|
Ligands | 2 | 2023 | 3293 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2005 | 2638 | 0.040 |
Why?
|
Drosophila melanogaster | 2 | 2018 | 1704 | 0.040 |
Why?
|
Caspase 8 | 3 | 2005 | 195 | 0.040 |
Why?
|
Gene Silencing | 1 | 2005 | 1538 | 0.040 |
Why?
|
Germinal Center | 1 | 2021 | 377 | 0.040 |
Why?
|
Macrophages | 1 | 2012 | 5655 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2023 | 1284 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2003 | 2088 | 0.040 |
Why?
|
Carcinoma | 1 | 2009 | 2374 | 0.040 |
Why?
|
Models, Biological | 3 | 2012 | 9581 | 0.040 |
Why?
|
Vesicle-Associated Membrane Protein 2 | 1 | 2017 | 20 | 0.040 |
Why?
|
Treatment Failure | 1 | 2004 | 2615 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2021 | 6608 | 0.040 |
Why?
|
Binding Sites | 2 | 2021 | 6115 | 0.040 |
Why?
|
STAT Transcription Factors | 1 | 2018 | 182 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3731 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3507 | 0.040 |
Why?
|
Transgenes | 1 | 2021 | 1009 | 0.040 |
Why?
|
Middle Aged | 17 | 2021 | 213127 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 2013 | 12071 | 0.040 |
Why?
|
Aged | 14 | 2021 | 162944 | 0.040 |
Why?
|
Combined Modality Therapy | 4 | 2013 | 8621 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2003 | 971 | 0.030 |
Why?
|
Prednisone | 2 | 2012 | 1567 | 0.030 |
Why?
|
Carrier Proteins | 2 | 2007 | 5019 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2021 | 1417 | 0.030 |
Why?
|
Drug Design | 1 | 2021 | 1078 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 230 | 0.030 |
Why?
|
DNA Methylation | 1 | 2009 | 4282 | 0.030 |
Why?
|
Forecasting | 1 | 2004 | 2948 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2005 | 2906 | 0.030 |
Why?
|
Transfection | 1 | 2003 | 5892 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2012 | 2713 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2002 | 1613 | 0.030 |
Why?
|
Melphalan | 2 | 2010 | 431 | 0.030 |
Why?
|
Prostatectomy | 1 | 2004 | 1871 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 839 | 0.030 |
Why?
|
Perphenazine | 1 | 2014 | 34 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2014 | 170 | 0.030 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2007 | 215 | 0.030 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2005 | 49 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2004 | 5062 | 0.030 |
Why?
|
Rhodamine 123 | 1 | 2013 | 38 | 0.030 |
Why?
|
Naphthoquinones | 1 | 2013 | 77 | 0.030 |
Why?
|
Pigmentation | 1 | 2014 | 148 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6540 | 0.030 |
Why?
|
Osteogenesis | 1 | 2020 | 1299 | 0.030 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2013 | 57 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6474 | 0.030 |
Why?
|
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 91 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2002 | 2968 | 0.030 |
Why?
|
Dopamine Antagonists | 1 | 2014 | 296 | 0.030 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 3504 | 0.030 |
Why?
|
Fatigue | 2 | 2010 | 1526 | 0.030 |
Why?
|
Chromatography, Affinity | 1 | 2014 | 549 | 0.030 |
Why?
|
Biomedical Research | 1 | 2008 | 3306 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2014 | 742 | 0.030 |
Why?
|
Rats | 1 | 2009 | 24265 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4328 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2013 | 3139 | 0.030 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2012 | 63 | 0.030 |
Why?
|
Costa Rica | 1 | 2012 | 177 | 0.030 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 345 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 4929 | 0.030 |
Why?
|
Caspase 9 | 2 | 2002 | 188 | 0.030 |
Why?
|
U937 Cells | 1 | 2012 | 268 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2013 | 247 | 0.030 |
Why?
|
Aged, 80 and over | 6 | 2014 | 57683 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2012 | 246 | 0.030 |
Why?
|
Incidence | 3 | 2015 | 20928 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2017 | 1086 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2014 | 370 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2017 | 2940 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2006 | 15056 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 647 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2012 | 259 | 0.020 |
Why?
|
Adult | 11 | 2021 | 213712 | 0.020 |
Why?
|
Drug Delivery Systems | 2 | 2017 | 2217 | 0.020 |
Why?
|
Receptors, Thrombopoietin | 1 | 2012 | 156 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2013 | 3199 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 657 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 2013 | 5519 | 0.020 |
Why?
|
Area Under Curve | 1 | 2014 | 1653 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 452 | 0.020 |
Why?
|
Peptides | 1 | 2002 | 4392 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9679 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 1525 | 0.020 |
Why?
|
beta Catenin | 1 | 2015 | 1058 | 0.020 |
Why?
|
Phenotype | 2 | 2021 | 16331 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 526 | 0.020 |
Why?
|
Safety | 2 | 2006 | 1185 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 627 | 0.020 |
Why?
|
Cysteine | 1 | 2014 | 873 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 193 | 0.020 |
Why?
|
Lentivirus | 1 | 2012 | 501 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 738 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 848 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 156 | 0.020 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 507 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2018 | 2440 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 804 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 697 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 21821 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1692 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1119 | 0.020 |
Why?
|
Epigenomics | 1 | 2014 | 902 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Biological Transport | 1 | 2013 | 2119 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2012 | 774 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9735 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 2842 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 1337 | 0.020 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2010 | 404 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 139 | 0.020 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3691 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 974 | 0.020 |
Why?
|
Central Nervous System | 1 | 2015 | 1354 | 0.020 |
Why?
|
Molecular Structure | 1 | 2012 | 1907 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1625 | 0.020 |
Why?
|
Blood Coagulation | 1 | 2012 | 1126 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2271 | 0.020 |
Why?
|
Estradiol | 1 | 2014 | 2021 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39004 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2009 | 527 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2018 | 3678 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2013 | 13029 | 0.020 |
Why?
|
Risk Management | 1 | 2010 | 571 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 498 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2017 | 3081 | 0.020 |
Why?
|
Nanoparticles | 1 | 2017 | 1902 | 0.020 |
Why?
|
Disease Progression | 3 | 2011 | 13256 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2010 | 874 | 0.020 |
Why?
|
Genetic Testing | 1 | 2018 | 3439 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 2009 | 4147 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2013 | 1915 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2014 | 1899 | 0.020 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 59 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2012 | 1221 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7153 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2013 | 1255 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 1811 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2015 | 5425 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2005 | 217 | 0.020 |
Why?
|
Prospective Studies | 4 | 2012 | 53187 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3862 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3465 | 0.010 |
Why?
|
Child | 3 | 2022 | 77478 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 1123 | 0.010 |
Why?
|
Azacitidine | 1 | 2005 | 347 | 0.010 |
Why?
|
Myeloma Proteins | 1 | 2002 | 70 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6756 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5212 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2012 | 2867 | 0.010 |
Why?
|
Base Sequence | 1 | 2014 | 12797 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1515 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2006 | 676 | 0.010 |
Why?
|
Cyclins | 1 | 2005 | 601 | 0.010 |
Why?
|
Cytochrome c Group | 1 | 2002 | 128 | 0.010 |
Why?
|
Zebrafish | 1 | 2014 | 2990 | 0.010 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2005 | 233 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2781 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4024 | 0.010 |
Why?
|
Enzyme Precursors | 1 | 2002 | 176 | 0.010 |
Why?
|
Autoimmunity | 1 | 2009 | 1348 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2013 | 2723 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11363 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5100 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2712 | 0.010 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 272 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 4187 | 0.010 |
Why?
|
Anemia | 1 | 2010 | 1499 | 0.010 |
Why?
|
Pyridines | 1 | 2012 | 2818 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2004 | 1155 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2003 | 525 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2009 | 2556 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 1970 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1668 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2009 | 2107 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 2002 | 563 | 0.010 |
Why?
|
Acetylation | 1 | 2003 | 1085 | 0.010 |
Why?
|
Medical Oncology | 1 | 2011 | 2235 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6259 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 18112 | 0.010 |
Why?
|
Heat-Shock Proteins | 1 | 2002 | 822 | 0.010 |
Why?
|
Constipation | 1 | 2002 | 546 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19862 | 0.010 |
Why?
|
Neutropenia | 1 | 2002 | 891 | 0.010 |
Why?
|
Protein Binding | 1 | 2009 | 9387 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2004 | 1887 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14554 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2006 | 1237 | 0.010 |
Why?
|
Doxorubicin | 1 | 2002 | 2215 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 3701 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14720 | 0.010 |
Why?
|
Pain | 1 | 2010 | 4961 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2002 | 1171 | 0.010 |
Why?
|
Viral Proteins | 1 | 2002 | 1899 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7276 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15194 | 0.010 |
Why?
|
Genotype | 1 | 2009 | 12946 | 0.010 |
Why?
|
Logistic Models | 1 | 2009 | 13403 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 9941 | 0.010 |
Why?
|
DNA Damage | 1 | 2002 | 2423 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2002 | 1617 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 21719 | 0.010 |
Why?
|
Cohort Studies | 1 | 2012 | 40450 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15494 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 72145 | 0.000 |
Why?
|